Quality-adjusted lifetime (QAL) is an important component in evaluation of clinical trials. In a seminal paper, Gelber et al. (1989) claimed that the Kaplan-Meier estimator is inconsistent in estimating the distribution of QAL under the presence of censoring. However, in this article, we show that, with appropriate censoring indexing, the Kaplan-Meier estimator actually is consistent in some practically important QAL data settings. Copyright © 2013 Grace Scientific Publishing, LLC
SUMMARY. Quality of life is an important component in the evaluation of clinical trials. A measure c...
Most follow-up studies are conducted to determine the survival rates of subjects affected by a speci...
One of the primary problems facing statisticians who work with survival data is the loss of in-forma...
In clinical trials of chronic diseases such as AIDS, cancer or cardiovascular diseases, the concept ...
This study aimed to compare estimations of Kaplan-Meier (K-M) and Weighted Kaplan-Meier (W-K-M) as a...
National audienceMedian follow-up is often used to assess the quality of follow-up in longitudinal s...
In many medical studies majority of the study subjects do not reach to the event of interest during ...
<p>Kaplan-Meier estimates of disease-free survival (A), relapse-free survival (B), and overall survi...
In many clinical trials, patients are not followed continuously. This means their vital status may n...
International audienceIntroduction: In this article, we only focus on the probability distributions ...
The 5-year survival rate is a good prognostic indicator for patients with Gastric cancer that is usu...
Kaplan Meier estimates of death-censored graft survival in patients with IgAN recurrence in the graf...
One way of examining trade-offs between quantity and quality of life (QOL) is to combine them into a...
<p>Kaplan-Meier estimates of Overral survival and disease-free survival for patients receiving with ...
Analyzing events over time is often complicated by incomplete, or censored, observations. Special no...
SUMMARY. Quality of life is an important component in the evaluation of clinical trials. A measure c...
Most follow-up studies are conducted to determine the survival rates of subjects affected by a speci...
One of the primary problems facing statisticians who work with survival data is the loss of in-forma...
In clinical trials of chronic diseases such as AIDS, cancer or cardiovascular diseases, the concept ...
This study aimed to compare estimations of Kaplan-Meier (K-M) and Weighted Kaplan-Meier (W-K-M) as a...
National audienceMedian follow-up is often used to assess the quality of follow-up in longitudinal s...
In many medical studies majority of the study subjects do not reach to the event of interest during ...
<p>Kaplan-Meier estimates of disease-free survival (A), relapse-free survival (B), and overall survi...
In many clinical trials, patients are not followed continuously. This means their vital status may n...
International audienceIntroduction: In this article, we only focus on the probability distributions ...
The 5-year survival rate is a good prognostic indicator for patients with Gastric cancer that is usu...
Kaplan Meier estimates of death-censored graft survival in patients with IgAN recurrence in the graf...
One way of examining trade-offs between quantity and quality of life (QOL) is to combine them into a...
<p>Kaplan-Meier estimates of Overral survival and disease-free survival for patients receiving with ...
Analyzing events over time is often complicated by incomplete, or censored, observations. Special no...
SUMMARY. Quality of life is an important component in the evaluation of clinical trials. A measure c...
Most follow-up studies are conducted to determine the survival rates of subjects affected by a speci...
One of the primary problems facing statisticians who work with survival data is the loss of in-forma...